tirzepatide nano microneedle patch weight loss Lmipki® NIDDK-Tirzepatide Nana Microneedle Patch Loose Weighy

Add-on to metformin SURPASS-2 (NCT03987919) was a 40-week open-label trial (double-blind with respect to MOUNJARO dose assignment) that randomized 1879 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin alone to the addition of subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, or MOUNJARO 15 mg once weekly or subcutaneous semaglutide 1 mg once weekly

According to Association for the Study of Obesity data, around 90% of weight-loss medication users access Mounjaro privately and, therefore, rely on independent providers for guidance and support when making choices that have been impacted or influenced by the cost increases in recent times 2

Genetics, lifestyle, hormonal balance, and gut microbiota may influence how well a person responds

Additional findings published in January 2025, along with actions taken by the Danish Medicines Agency, prompted further scrutiny of the drugs vision-related side effects

One way to interpret this figure is to select a change in body weight of interest on the horizontal axis and note the corresponding proportions of patients (vertical axis) in each treatment group who achieved at least that degree of weight reduction

The study was a double-blind, placebo-controlled trial with participants receiving once-weekly subcutaneous doses of tirzepatide or a placebo